ArticleJournal of clinical immunology2013
Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus.
Article in Journal of clinical immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Association of IL-37 levels and genetic variants with systemic lupus erythematosus: a meta-analysis.Scientific reports · 2025Pooled it
- Correlation between circulating interleukin-18 level and systemic lupus erythematosus: a meta-analysis.Scientific reports · 2021Pooled it
- Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus.Scientific reports · 2016Trial
- Elevated serum IL-18 and IL-37 levels and their association with seizure burden in paediatric epilepsy.Frontiers in immunology · 2026Article
- The Potential Contribution of the IL-37/IL-18/IL-18BP/IL-18R Axis in the Pathogenesis of Sjögren's Syndrome.International journal of molecular sciences · 2025Article
- Anti-Inflammatory Effect of Atorvastatin and Rosuvastatin on Monosodium Urate-Induced Inflammation through IL-37/Smad3-Complex Activation in an In Vitro Study Using THP-1 Macrophages.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Biology of interleukin-37 and its role in autoimmune diseases (Review).Experimental and therapeutic medicine · 2022Review
- Interleukin-1 in Coronary Artery Disease.Current topics in medicinal chemistry · 2022Article
- The intellectual base and research fronts of IL-37: A bibliometric review of the literature from WoSCC.Frontiers in immunology · 2022Review
- Activation of CpG-ODN-Induced TLR9 Signaling Inhibited by Interleukin-37 in U937 Human Macrophages.Yonsei medical journal · 2021Article
- Elevated levels of serum IL-36α in patients with systemic lupus erythematosus.Biomedical reports · 2021Article
- IL-37bΔ1-45 suppresses the migration and invasion of endometrial cancer cells by targeting the Rac1/NF-κB/MMP2 signal pathway.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Different Features of Interleukin-37 and Interleukin-18 as Disase Activity Markers of Adult-Onset Still's Disease.Journal of clinical medicine · 2021Article
- Circulating Interleukin-37 Levels in Healthy Adult Humans - Establishing a Reference Range.Frontiers in immunology · 2021Article
- Correlation Between Level of Interleukin-37 and Rheumatoid Arthritis Progression.International journal of general medicine · 2021Article
- GILZ Regulates the Expression of Pro-Inflammatory Cytokines and Protects Against End-Organ Damage in a Model of Lupus.Frontiers in immunology · 2021Article
- Entecavir downregulates interleukin-37 in patients with chronic active hepatitis B infection.The Journal of international medical research · 2020Observational
- The IL-1 family of cytokines and receptors in rheumatic diseases.Nature reviews. Rheumatology · 2019Review
- Plasma levels and expression of interleukin-37 in patients with immune thrombocytopenia.Experimental and therapeutic medicine · 2019Article
- Human gut derived-organoids provide model to study gluten response and effects of microbiota-derived molecules in celiac disease.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to research the expression of IL-37 in systemic lupus erythematosus (SLE) patients and the effect of glucocorticoid on IL-37. Thirty newly diagnosed severe SLE patients receiving prednisone 1 mg/kg/day for 14 consecutive days and 30 healthy subjects were enrolled into this study. The plasma levels of IL-37 and other cytokines were detected by ELISA and the relative mRNA amounts of IL-37 and other cytokines were detected by RT-PCR. The plasma levels of IL-37, IL-18, IL-18BP, IFN-γ, and IL-6 in SLE patients increased significantly compared with healthy controls (p<0.05). The relative amount of IL-37 mRNA increased by 2.45-fold in pre-treatment SLE patients compared with controls (p<0.05). Plasma concentrations of IL-37 correlated with IL-18, IL-18BP, IFN-γ, IL-6 and SLEDAI score in both pre-treatment and post-treatment SLE patients. The plasma levels of IL-37 decreased significantly after treatment of glucocorticoid. The relative amount of IL-37 mRNA decreased by 24.5 % in post-treatment SLE patients compared with pre-treatment ones (p<0.01). In conclusion, IL-37 is upregulated in active SLE patients. IL-37 is correlated with pro-inflammatory cytokines and SLEDAI. Glucocorticoid can downregulate the expression of IL-37 and other cytokines in SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.